A Multi-Center Randomized Clinical Trial Correlating the Effects of 24 Months of Exemestane or Letrozole on Surrogate Markers of Response With Aromatase Polymorphism

Trial Profile

A Multi-Center Randomized Clinical Trial Correlating the Effects of 24 Months of Exemestane or Letrozole on Surrogate Markers of Response With Aromatase Polymorphism

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 01 Jul 2017

At a glance

  • Drugs Exemestane (Primary) ; Letrozole (Primary)
  • Indications Early breast cancer
  • Focus Pharmacodynamics; Pharmacogenomic; Therapeutic Use
  • Acronyms ELPh
  • Most Recent Events

    • 01 Jul 2017 According to results published in the Breast Cancer Research and Treatment Journal, after 132 patients had been enrolled, an amendment to the protocol allowed patients with self-reported intolerance to the aromatase inhibitor (AI) to which they were originally randomized to crossover to the other study-provided AI.
    • 15 Dec 2011 Results assessing the effect of treatment on lipid parameters published in the Journal of Clinical Pharmacology.
    • 15 Dec 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top